AMERGE Drug Patent Profile
✉ Email this page to a colleague
When do Amerge patents expire, and when can generic versions of Amerge launch?
Amerge is a drug marketed by Glaxosmithkline Llc and is included in one NDA.
The generic ingredient in AMERGE is naratriptan hydrochloride. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the naratriptan hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AMERGE?
- What are the global sales for AMERGE?
- What is Average Wholesale Price for AMERGE?
Summary for AMERGE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 103 |
| Clinical Trials: | 4 |
| Patent Applications: | 503 |
| Drug Prices: | Drug price information for AMERGE |
| What excipients (inactive ingredients) are in AMERGE? | AMERGE excipients list |
| DailyMed Link: | AMERGE at DailyMed |
Recent Clinical Trials for AMERGE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Hartford HealthCare | Phase 1/Phase 2 |
| GlaxoSmithKline | |
| Clinvest | Phase 4 |
US Patents and Regulatory Information for AMERGE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | AMERGE | naratriptan hydrochloride | TABLET;ORAL | 020763-002 | Feb 10, 1998 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Glaxosmithkline Llc | AMERGE | naratriptan hydrochloride | TABLET;ORAL | 020763-001 | Feb 10, 1998 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for AMERGE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline Llc | AMERGE | naratriptan hydrochloride | TABLET;ORAL | 020763-002 | Feb 10, 1998 | 4,997,841 | ⤷ Subscribe |
| Glaxosmithkline Llc | AMERGE | naratriptan hydrochloride | TABLET;ORAL | 020763-001 | Feb 10, 1998 | 4,997,841 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for AMERGE
See the table below for patents covering AMERGE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 0303506 | ⤷ Subscribe | |
| Yugoslavia | 30689 | ⤷ Subscribe | |
| Canada | 1310968 | DERIVES INDOLE (INDOLE DERIVATIVES) | ⤷ Subscribe |
| Finland | 883744 | ⤷ Subscribe | |
| Denmark | 455488 | ⤷ Subscribe | |
| South Korea | 0131327 | ⤷ Subscribe | |
| United Kingdom | 8719167 | ⤷ Subscribe | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for AMERGE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0303507 | 97C0102 | Belgium | ⤷ Subscribe | PRODUCT NAME: NARATRIPTAN HYDROCHLORIDUM; REGISTRATION NO/DATE: 725 IS 278 F 3 19970818; FIRST REGISTRATION: SE 13382 19970310 |
| 0303507 | 64/1997 | Austria | ⤷ Subscribe | PRODUCT NAME: ''NARATRIPTAN'', GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATES EINSCHLIESSLICH DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: 1-22059 19970731; FIRST REGISTRATION: SE 13382 19970310 |
| 0303507 | C970035 | Netherlands | ⤷ Subscribe | PRODUCT NAME: NARATRIPTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAA RDBAAR ZOUT OF SOLVAAT, IN HET BIJZONDER NARATRIPTAN-HYDROCHLOR IDE; NAT. REGISTRATION NO/DATE: RVG 21444 19970801; FIRST REGISTRATION: SE 13382 19970310 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
